Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain des Candidates study

American Heart Journal

Volumn 166, Issue 5, 2013, Pages 831-838

  Valgimigli, Marco ^a,b   Patialiakas, Athanasios ^a   Thury, Attila ^c   Colangelo, Salvatore ^d   Campo, Gianluca ^a   Tebaldi, Matteo ^a   Ungi, Imre ^c   Tondi, Stefano ^e   Roffi, Marco ^f   Menozzi, Alberto ^g   De Cesare, Nicoletta ^h   Garbo, Roberto ^d   Meliga, Emanuele ⁱ   Testa, Luca ^j   Gabriel, Henrique M ^k   Airoldi, Flavio ^l   Ferlini, Marco ^m   Liistro, Francesco ⁿ   Dellavalle, Antonio ^o   Vranckx, Pascal ^p   Briguori, Carlo ^q   more..

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Cardiology Center   (Hungary)

^d San Giovanni Bosco   (Italy)

^e District of Vignola   (Italy)

^f UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h Policlinico S Marco   (Italy)

ⁱ MAURIZIANO HOSPITAL   (Italy)

^j San Donato Polyclinic and Institute for Research and Care   (Italy)

^k HOSPITAL DE SANTA CRUZ   (Portugal)

^l IRCCS MULTIMEDICA   (Italy)

^m FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁿ IRCCS POLICLINICO SAN DONATO   (Italy)

^o ASL 17   (Italy)

^p VIRGA JESSE HOSPITAL   (Belgium)

^q Clinica Mediterranea   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOY; CLOPIDOGREL; COBALT; EVEROLIMUS; PACLITAXEL; PHOSPHORYLCHOLINE; RAPAMYCIN; ZOTAROLIMUS;

ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEVICE SAFETY; DRUG ELUTING STENT; DRUG RELEASE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUNGARY; IMPLANTATION; ITALY; LOADING DRUG DOSE; PORTUGAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SWITZERLAND; TREATMENT DURATION;

EID: 84886953167     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.07.033     Document Type: Article

References (23)

1. M. Valgimigli, G. Campo, and G. Percoco Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 15 2008 1788 1799
2. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 10 2007 1030 1039
3. J.V. Tu, J. Bowen, and M. Chiu Effectiveness and safety of drug-eluting stents in Ontario N Engl J Med 357 14 2007 1393 1402
4. M. Valgimigli, G. Campo, and S. Gambetti Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) Int J Cardiol 165 1 2013 134 141
5. S.E. Burke, R.E. Kuntz, and L.B. Schwartz Zotarolimus (ABT-578) eluting stents Adv Drug Deliv Rev 58 3 2006 437 446
6. L. Mauri, J.M. Massaro, and S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents JACC Cardiovasc Interv 3 12 2010 1240 1249
7. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet;380(9851):1396-405.
8. J. Fajadet, W. Wijns, and G.J. Laarman Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 6 5 2010 562 567
9. D.E. Kandzari, L. Mauri, and J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 4 5 2011 543 550
10. A.J. Kirtane, M.B. Leon, and M.W. Ball The "Final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent JACC Cardiovasc Interv 6 4 2013 325 333
11. T. Pilgrim, L. Raber, and A. Limacher Comparison of titanium-nitride- oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial JACC Cardiovasc Interv 4 6 2011 672 682
12. E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 9851 2012 1396 1405
13. M. Maeng, H.H. Tilsted, and L.O. Jensen 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents JACC Cardiovasc Interv 5 8 2012 812 818
14. D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 15 2010 1187 1195
15. C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 10 2009 1370 1376
16. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 23 2010 2536 2543
17. B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 15 2012 1340 1348
18. W.C. Kang, T. Ahn, and K. Lee Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 7 8 2011 936 943
19. M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 2015 2026
20. D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents JACC Cardiovasc Interv 4 10 2011 1119 1128
21. J.S. Kim, I.K. Jang, and C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial JACC Cardiovasc Interv 2 12 2009 1240 1247
22. Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J; [Epub ahead of print].
23. M. Valgimigli, M. Borghesi, and M. Tebaldi Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 12 2013 909 919